Attributable Mortality of Nosocomial Candidemia, Revisited

Clinical Infectious Diseases

Volumn 37, Issue 9, 2003, Pages 1172-1177

  Gudlaugsson, Olafur ^a,d,e   Gillespie, Shane ^b   Lee, Kathleen ^b   Vande Berg, Jeff ^b   Hu, Jianfang ^b   Messer, Shawn ^c   Herwaldt, Loreen ^a,b,d   Pfaller, Michael ^a,c   Diekema, Daniel ^b,c,d,f  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA HEALTH CARE   (United States)

^c Medical Microbiology Division   (United States)

^d UNIVERSITY OF IOWA   (United States)

^e LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^f UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE;

ADULT; ARTICLE; CANDIDA; CANDIDA ALBICANS; CANDIDIASIS; COHORT ANALYSIS; CONTROLLED STUDY; CRUDE MORTALITY; FEMALE; HOSPITAL INFECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATIENT SELECTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS;

AGE FACTORS; ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; COHORT STUDIES; CROSS INFECTION; FEMALE; FLUCONAZOLE; FUNGEMIA; HUMANS; LENGTH OF STAY; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; RETROSPECTIVE STUDIES; SEX FACTORS; SURVIVAL RATE;

EID: 0242659142     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/378745     Document Type: Article

References (32)

1. National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1990-May 1999, issued June 1999. Am J Infect Control 1999; 27:520-32.
2. Edmond MB, Wallace SE, McClish DK, et al. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis 1999; 29:239-44.
3. Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP. Hospital acquired candidemia: attributable mortality and excess length of stay. Arch Intern Med 1988; 148:2642-5.
4. Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after bone marrow transplantation: a prospective, randomized, double-blind study. J Infect Dis 1995; 171:1545-52.
5. Man KA, Seidel K, Slavin MA, et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood 2000; 96:2055-61.
6. Trick WE, Fridkin SK, Edwards JR, Hajjeh RA, Gaynes RP. Secular trend of hospital acquired candidemia among intensive care unit patients in the United States during 1989-1999. The National Nosocomial Infections Surveillance System Hospitals. Clin Infect Dis 2002; 35:627-30.
7. Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347: 2020-9.
8. Ally R, Schurmann D, Kreisel W, et al. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis 2001; 33:1447-54.
9. Charlson ME, Pompei PP, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40:373-83.
10. NCCLS. Reference method for broth dilution antifungal susceptibility testing of yeasts: approved standard. NCCLS document M27-A. Wayne, PA: NCCLS, 1997.
11. Rex JH, Walsh TJ, Sobel JD, et al. Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. Clin Infect Dis 2000; 30:662-78.
12. Fraser VJ, Jones M, Dunkel J, Storfer S, Medoff G, Dunagan WC. Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clin Infect Dis 1992; 15:414-21.
13. Harvey RL, Myers JP. Nosocomial fungemia in a large community teaching hospital. Arch Intern Med 1987; 147:2117-20.
14. Horn R, Wong B, Kiehn TE, Armstrong D. Fungemia in a cancer hospital: changing frequency, earlier onset, and results of therapy. Rev Infect Dis 1985; 7:646-55.
15. Klein JJ, Watanakunakorn C. Hospital-acquired fungemia: its natural course and clinical significance. Am J Med 1979; 67:51-8.
16. Komshian SV, Uwaydah AK, Sobel JD, Crane LR. Fungemia caused by Candida species and Torulopsis glabrata in the hospitalized patient: frequency, characteristics, and evaluation of factors influencing outcome. Rev Infect Dis 1989; 11:379-90.
17. Marsh PK, Tally FP, Kellum J, Callow A, Gorbach SL. Candida infections in surgical patients. Ann Surg 1983; 198:42-7.
18. Pittet D, Tarara D, Wenzel RP. Nosocomial bloodstream infection in critically ill patients: excess length of stay, extra costs, and attributable mortality. JAMA 1994; 271:1598-601.
19. Weinstein MP, Towns ML, Quartey SM, et al. The clinical significance of positive blood cultures in the 1990s: a prospective comprehensive evaluation of the microbiology, epidemiology, and outcome of bacteremia and fungemia in adults. Clin Infect Dis 1997; 24:584-602.
20. Elixhauser A, Yu K, Steiner C, Bierman AS. Hospitalization in the United States, 1997: HCUP fact book no. 1. Agency for Healthcare Research and Quality (AHRQ) publication no. 00-0031. Rockville, MD: AHRQ, 2000.
21. Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med 1994; 331:1325-30.
22. Edmond MB, Ober JF, Dawson JD, et al. Vancomycin-resistant enterococcal bacteremia: natural history and attributable mortality. Clin Infect Dis 1996; 23:1234-9.
23. Martin MA, Pfaller MA, Wenzel RP. Coagulase-negative staphylococcal bacteremia, mortality and hospital stay. Ann Intern Med 1989; 110:9-16.
24. Redondo CM, Arbo MDJ, Grindlinger J, Snydman DR. Attributable mortality of bacteremia associated with the Bacteroides fragilis group. Clin Infect Dis 1995; 20:1492-6.
25. Senol E, Desjardin J, Stark PC, Barefoot L, Snydman DR. Attributable mortality of Stenotrophomonas maltophilia bacteremia. Clin Infect Dis 2002; 34:1653-6.
26. Rello J. Impact of nosocomial infections on outcome: myths and evidence. Infect Control Hosp Epidemiol 1999; 20:392-4.
27. Pittet D, Li N, Woolson RF, Wenzel RP. Microbiological factors influencing outcome of nosocomial bloodstream infection: a 6-year validated, population-based model. Clin Infect Dis 1997; 24:1068-78.
28. Pfaller MA, Diekema DJ. Role of sentinel surveillance of candidemia: trends in species distribution and antifungal susceptibility. J Clin Microbiol 2002; 40:3551-7.
29. McNeil MM, Nash SL, Hajjeh RA, et al. Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin Infect Dis 2001; 33:641-7.
30. O'Grady NP, Alexander M, Dellinger EP, et al. Guidelines for the prevention of intravascular catheter-related infections. MMWR Recomm Rep 2002; 51(RR-10):1-29.
31. Coopersmith CM, Rebmann TL, Zack JE, et al. Effect of an education program on decreasing catheter-related bloodstream infections in the surgical intensive care unit. Crit Care Med 2002; 30:59-64.
32. Sobel JD, Rex JH. Invasive candidiasis: turning risk into a practical prevention policy? Clin Infect Dis 2001; 33:187-90.